To reduce the likelihood of people giving up on PrEP because of difficulty committing to multiple annual visits, a team of investigators created PrEP@Home, a home-based monitoring system that will allow people on the PrEP regimen to meet with their health care providers just once a year, its creators say.
A recent study analyzed how health systems utilize and integrate virtual care into their daily practice.
Under the rule, prescription rebates may be passed directly to patients at the pharmacy counter, effectively creating a new safe harbor designed for price reductions at the point of sale.
The findings are further evidence of the impact of an active lifestyle on physical health.
Ado-trastuzumab emtansine (Kadcyla) is currently approved for the treatment of patients with HER-2 positive metastatic breast cancer who previously received trastuzumab and a taxane.
The proposed rule aims to encourage drug manufacturers to pass discounts directly to patients and improve transparency in the market.
Top news of the day across the health care landscape.
Top news of the day across the health care landscape.
The risk of a solid subsequent malignant neoplasm is elevated in survivors of childhood Hodgkin lymphoma, according to an extended follow-up of more than 25 years.
The disproportionate impact on the US African-American population is highlighted each year on February 7, National Black HIV/AIDS Awareness Day.
Officials with the FDA have approved caplacizumab-yhdp (Cablivi, Sanofi) injection for the treatment of adults with acquired thrombotic thrombocytopenic purpura (aTTP), a rare and life-threatening blood clotting autoimmune disorder.
Caplacizumab-yhdp (Cablivi, Sanofi) is a targeted treatment designed to inhibit the formation of blood clots in adults with acquired thrombotic thrombocytopenic purpura.
The 2010 remanufacturing of Purdue Pharma's OxyContin (oxycodone) into an "abuse-deterrent formulation" has been identified as a key contributing factor in opioid abusers switching to heroin injections and the corresponding surge in hepatitis C virus (HCV) infections, according to a new Rand Corporation study.
Data from 2 phase 3 trials showed significant improvement in disease activity in patients with moderate-to-severe atopic dermatitis treated with baricitinib (Olumiant).
Researchers at University of Texas Health Science Center at San Antonio studied 28,000 childhood cancer survivors to determine similarities in long-term effects for various chemotherapies.
Despite efforts to ease cost burden for Medicare Part D beneficiaries, high out-of-pocket costs for specialty tier drugs continue to be a concern for patients without low-income subsidies.
Top news of the day across the health care landscape.
Top news of the day across the health care landscape.
Injection drug use has been identified as a predominant risk factor for hepatitis C infection and the opioid epidemic has been suggested as a driver of a recent rise in infections.
Along with providing screenings every Thursday in February, including Valentine’s Day, at MinuteClinlic locations nationwide, CVS has also extended its support to American Heart Association’s Go Red for Women with new $15 million commitment.
Real pharmacists speak out about the alleged fake Walgreens pharmacist.
A New Drug Application (NDA) and a supplemental NDA (sNDA) were accepted for the Priority Review for products being developed by Merck.
Medicare Part D patients can face thousands of dollars in out-of-pocket costs for a single specialty tier drug.
Research seeks to uncover the mechanisms underlying the surging rate of Parkinson disease diagnoses.
Several states have passed laws restricting initial opioid prescribing as a method to address the opioid epidemic.
Top news of the day across the health care landscape.
Top news of the day across the health care landscape.
HIV-positive patients with hepatocellular carcinoma had an adjusted 24% increased hazard of death compared to their HIV-negative peers.
Dr. Reddy’s Laboratories is continuing its voluntary nationwide recall of the antiepileptic drug Levetiracetram in 0.54% Sodium Chloride Injection, 1,500 mg/100 mL (15 mg/mL) in single-dose infusion bags to the hospital level in the United States.
The global hepatitis C virus epidemic faces several barriers and meeting WHO target goals will be difficult unless a vast strategy is implemented.
